Volition Overall Highlights
- Multiple products already launched
- Proven Licensing model, validated in Vet
- Multiple multi-Bn dollar TAM markets
- Low-cost, scalable platform with high margins
- Asset light - no need for their machines, labs, or sales reps
- In confidential licensing discussions with more than a dozen large diagnostic and liquid biopsy companies worldwide, first deals signed in Q3 2025
- Anticipate use in routine clinical practice in 2026
Grab Sources And More Here: VNRX Website. VNRX Presentation. -----
And as I mentioned earlier, (NYSE American: VNRX) has several potential catalysts of focus. Take a look:
#1. VNRX Potential Catalyst - A Significant Analyst Target ($16.83) May Signal Quadruple-Digit Potential Upside.
Back in April, Zacks Small-Cap Research analyst, Steven Ralston, provided an update to coverage on (NYSE American: VNRX) with a price target of $16.83.
From Tuesday's closing valuation, this target suggests a potential upside of 2,200+%.
Here's some report highlights:
Valuation
Utilizing a financial model based on DCF methodology, which forecasts out to 2033, and uses a 10% discount rate (based on CAPM), a 2% terminal growth rate and a terminal P/S multiple of 0.56, the indicated value of VNRX is $16.83 per share. The predominate factor for the lower target is the dilution resulting from the issuance of the Lind Global Asset Management XII LLC Notes (in 2025 and 2026). -----
#2. VNRX Potential Catalyst - A Low Float Under 7Mn Shares May Create A Potential Environment For Heightened Volatility.
According to info from the Yahoo Finance website, VNRX has a low float.
The website reports this profile to have roughly 6.65Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility potential.
If the company provides positive news during the 2nd half of 2026, could it help provide a breakout spark when paired with this volatility potential? -----
#3. VNRX Potential Catalyst - The Company's New Capture-Seq™ Liquid Biopsy Technology Gets First Peer Reviewed Paper Published.
Volition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy Technology
Targets $36Bn TAM in Early Cancer Detection and MRD.
Company in active discussions with global diagnostic leaders to accelerate commercialization.
HENDERSON, Nev., Aug. 5, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, was the first to demonstrate the isolation and analysis of >99% pure circulating tumor-derived DNA (ctDNA). Volition today announces the publication of the first peer-reviewed paper describing the technology in detail - entitled "Direct analysis of transcription factor protected cfDNA in plasma by ChIP-seq: Measurement of altered CTCF binding in cancer is a novel biomarker for liquid biopsy."
Most current liquid biopsy methods involve deep sequencing of plasma DNA and bioinformatic analysis of the data produced to identify the presence of cancer in a patient. The biggest problem facing all liquid biopsy methods worldwide is that the vast majority of circulating DNA in blood plasma samples comes from healthy cells, not cancer cells. Volition's new technology employs an entirely novel approach to liquid biopsy that has overcome this hurdle and produced >99% pure cancer associated plasma DNA sequence sets for liquid biopsy.
Mr. Gael Forterre, Chief Licensing Officer, Volition added:
"We are delighted that the paper detailing this breakthrough technology has been peer reviewed and published.
"We are in active discussions with several large liquid biopsy and diagnostic companies to accelerate the development of this technology, "Capture-Seq™", and indeed are in the process of undertaking technical evaluations with potential licensors.
"We believe the potential use cases for Capture-Seq™ represent a significant commercial opp. with a Total Addressable Market on an annualized basis of approximately $23Bn for the human Multi-Cancer Early Detection (MCED) use, and over $13Bn for Minimum Residual Disease (MRD)."
...
Read the full article here. -----
#4. VNRX Potential Catalyst - Commercialization Could Be Nearing Within A $3.8Bn Addressable Market.
Volition Advances Nu.Q® NETs Platform Towards Commercialization
Consistent international data positions Nu.Q® H3.1 as a potential "game changer" in sepsis management within a $3.8Bn addressable market
HENDERSON, Nev., July 30, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today provides a comprehensive update highlighting the significant clinical and scientific evidence amassed for its Nu.Q® NETs product. It also issued a video featuring Critical Care Lead and Medical Consultant to Volition, Dr Andrew Retter, who explains the scientific and clinical significance of these findings.
Mr. Gael Forterre, Chief Commercial Officer, Volition commented:
"We are in active discussions with several large diagnostic companies to accelerate the development of Nu.Q® NETs and believe the potential use cases represent a significant commercial opp. with a Total Addressable Market on an annualized basis of approximately $3.8Bn."
...
Read the full article here. -----
#5. VNRX Potential Catalyst - Key Oversold Leaning Technical Indicators Could Suggest A Healthy Reversal May Be Nearing.
At 2:30PM EST Tuesday, Barchart was reporting VNRX to have several oversold leaning technical indicators.
These technicals could be signaling a healthy reversal is approaching in the near term.
Here's the definition of a "reversal" from Investopedia:
"A reversal is a change in the price direction of an asset. A reversal can occur to the upside or downside. Following an uptrend, a reversal would be to the downside. Following a downtrend, a reversal would be to the upside. Reversals are based on overall price direction and are not typically based on one or two periods/bars on a chart."
Here are the technicals to pay close attention to (as of 2:30PM EST Tuesday):
- 9-Day Relative Strength Index: 23.73%
- 14-Day Relative Strength Index: 26.14%
When these numbers drop down to the 30% range and lower, they can be viewed as being in oversold territory. While in this territory, they can paint the picture of a profile that is undervalued.
- 9-Day Raw Stochastic %D: 12.69%
- 14-Day Raw Stochastic %D: 7.03%
As the Raw Stochastic nears the 10% range and lower it may also be viewed as oversold and undervalued. -----
(NYSE American: VNRX) Recap - 5 Potential Catalysts On Watch
#1. A Significant Analyst Target ($16.83) May Signal Quadruple-Digit Potential Upside.
#2. A Low Float Under 7Mn Shares May Create A Potential Environment For Heightened Volatility.
#3. The Company's New Capture-Seq™ Liquid Biopsy Technology Gets First Peer Reviewed Paper Published.
#4. Commercialization Could Be Nearing Within A $3.8Bn Addressable Market.
#5. Key Oversold Leaning Technical Indicators Could Suggest A Healthy Reversal May Be Nearing. -----
We're initiating coverage on VolitionRx Limited (NYSE American: VNRX).
Updates will be out soon. Keep your eyes peeled.
Sincerely, Kai Parker StockWireNews
(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) |
